重组人血小板生成素治疗血小板减少症的临床分析

目的探讨分析重组人血小板生成素治疗血小板减少症的临床疗效。方法选取采用rhTPO治疗的血小板减少症患者46例作为治疗组,选取同期采用rhIL-11治疗的血小板减少症46例作为对照组,比较两组的疗效。结果治疗组有效率为91.3%,对照组为76.1%,两组比较,差异有统计学意义（P〈0.05）。两组治疗前与治疗后血小板值以及用药持续时间比较差异均无统计学意义;血小板开始恢复时间治疗组明显低于对照组,两组比较,差异有统计学意义（P〈0.05）。结论重组人血小板生成素治疗血小板减少症临床疗效显著,值得推广应用。

Clinical Analysis of Recombinant Human Thrombopoietin Hormone Treatment of Thrombocytopenia

Objective To analyze the recombinant human thrombopoietin treatment of thrombocytopenia clinical efficacy. Methods Select thrombocytopenia using rhTPO treated 46 patients as a treatment group, select the same period rhIL-11 treatment of throm- bocytopenia in patients with 46 cases as the control group, the two groups were compared efficacy. Results Treatment group was 91.3%, 76.1% in the control group, the two groups（P〈0.05）, with statistical significance. Were not statistically significant difference between the two groups before treatment and after treatment platelet values, and the duration of use; platelet recovery time treat- ment group was significantly lower than the control group, two groups, P〈0.05, statistically significant. Conclusion The clinical ef- ficacy of recombinant human thrombopoietin treatment of thrombocytopenia significantly worth promoting.